Skip to main content

Peer Review reports

From: Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis

Original Submission
18 Nov 2024 Submitted Original manuscript
25 Nov 2024 Author responded Author comments - Jie Wu
3 Dec 2024 Author responded Author comments - Jie Wu
Resubmission - Version 2
25 Nov 2024 Submitted Manuscript version 2
8 Dec 2024 Reviewed Reviewer Report - Marcelo Antonini
29 Dec 2024 Reviewed Reviewer Report
2 Jan 2025 Reviewed Reviewer Report
4 Jan 2025 Reviewed Reviewer Report
20 Feb 2025 Author responded Author comments - Jie Wu
Resubmission - Version 3
20 Feb 2025 Submitted Manuscript version 3
Publishing
21 Feb 2025 Editorially accepted
7 Mar 2025 Article published 10.1186/s12905-025-03628-z

You can find further information about peer review here.

Back to article page